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Abstract
Introduction: Oral administration of a drug is the most common, ideal and preferred 
route of administration. The main problem of oral drug formulations is their low 
bioavailability arises from poor aqueous solubility of drug. Aqueous solubility of 
lipophilic drugs can be improved by various techniques like salt formation, 
complexation, addition of co-solvent etc. but self-emulsifying drug delivery system 
(SEDDS) is getting more attention for increasing the solubility of such drugs. The 
SEDDS is an isotropic mixture of drug, lipids, and emulsifiers, usually with one or 
more hydrophilic co-solvents/co-emulsifiers. This system is having ability to generate 
oil-in-water (o/w) emulsions or microemulsions upon gentle agitation followed by 
dilution with aqueous phase. The SEDDSs are relatively newer, lipid-based 
technological innovations possessing unparalleled potential in improving oral 
bioavailability of poorly water-soluble drugs.
Areas covered: This review provides updated information regarding the types of 
SEDDS, their preparation techniques, drug delivery and related recent patents along 
with marketed formulations.
Expert opinion: The SEDDS has been explored for improving bioavailability, rising 
intra-subject heterogeneity and increasing solubility. SEDDS offers the benefit of a 
protective effect against the hostile environment in the gut. The unique fabrication 
techniques provide specific strategy to overcome the low bioavailability and poor 
solubility problems.
Keywords: Self-emulsifying drug delivery system, solubility, drug delivery, patents, 
bioavailability
Page 2 of 53





























































For Peer Review Only
Article highlights
 Conceptually self-emulsifying drug delivery systems (SEDDS) are isotropic 
mixtures of drug, lipids, and emulsifiers, usually with one or more hydrophilic 
co-solvents/co-emulsifiers.
 The SEDDS possess a great potential in oral bioavailability enhancement of 
poorly water-soluble drugs.
 The process of self-emulsification is dependent on diverse factors such as the 
nature of oil, surfactant, cosurfactant, oil/surfactant ratio, and the polarity of 
the emulsion.
 Drug solubility plays a pivotal role in the selection of excipients in SEDDS 
formulation.
 SEDDS are proving themselves as promising nanocarriers for the efficient 
drug delivery.
1. Introduction
Around 50% of the novel drug entity has low aqueous solubility and is facing a 
drug delivery obstacle. Dissolution is the rate-limiting step for less soluble drugs, 
hence a small increase in dissolution rate sometimes leads to increase in the 
bioavailability. Formulation performance depends on the rate and extent of the drugs 
belonging to the Biopharmaceutical Classification System (BCS) Class II [1]. Self-
emulsifying drug delivery system (SEDDS) is a lipid-based formulation and an 
isotropic mixture of surfactants, oil phase, co-solvents and drug that form a milky 
emulsion with a submicrometric droplet size following mild agitation in water or 
gastrointestinal fluid [2]. The small globules produced increase the interfacial area 
allowing for a quicker release of drugs, which can increase the intestinal permeability 
of a number of drugs by stimulating lymphatic transport and bypassing the 
metabolism of the first step, thus improving drug bioavailability [2]. The SEDDS 
typically produces emulsion with a droplet size above 300 nm, however it may be 
vary from coarse to micron size while self-microemulsifying drug delivery system 
(SMEDDS) forms transparent microemulsions with a droplet size of 100-250 nm. The 
self-nanoemulsifying drug delivery system (SNEDDS) contains nanoemulsion with 
low quantity of surfactants with droplet size below 100 nm. These are physically 
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stable formulations as compared to the emulsions, which are sensitive and 
metastable dispersed forms. Thus, for lipophilic drug exhibiting dissolution rate 
limited absorption, these systems may offer an improvement in the rate and extent of 
absorption and result in more reproducible blood-time profiles [3-8]. The prime 
distinguished features of SEDDS, SMEDDS and SNEDDS are enlisted in Table 1.
Different fabrication techniques, types, characterization process and 
biomedical applications of SEDDS are depicted in Ishikawa fishbone diagram [Figure 
1]. The SEDDS shows some merits and demerits over the conventional drug delivery 
system, which are elaborated in Figure 2 [9-11].
The SEDDSs are relatively newer, lipid-based technological innovations 
possessing unparalleled potential in improving oral bioavailability of poorly water-
soluble drugs. These formulations have been shown to reduce the slow and 
incomplete dissolution of a drug, facilitate the formation of its solubilized phase, 
increase the extent of its transportation via the intestinal lymphatic system, and 
bypass the P-gp efflux, thereby augmenting drug absorption from the GI tract. The 
SEDDSs is one of the commercially feasible techniques and several products have 
been filed as new drug application (NDA) and abbreviated new drug application 
(ANDA). The commercially available SEDDS formulations include Sandimmune®, 
Neora® (Novartis Pharmaceuticals Corporation); Gengraf®, Norvir®, Depakene® 
(AbbVie Inc.); Fortovase®, Rocaltrol®, Vesanoid®, Accutane® (Roche Laboratories 
Inc.); Agenerase® (GlaxoSmithKline); Targretin® (Ligand Pharmaceuticals/ Eisai 
Ltd.); and Aptivus® (Boehringer Ingelheim Pharmaceuticals, Inc.). In totality, the 
present review furnishes an updated compilation of wide-ranging information on 
various requisite vistas of the self-emulsifying formulations, thus paving the way for 
accelerated progress into the SEDDS application in pharmaceutical research.
2. Composition of SEDDS
2.1. Surfactants
It is one of the essential components in the formulation, as they promote the 
emulsification properties. Surfactants, being amphiphilic in nature, can dissolve (or 
solubilize) relatively high amounts of hydrophobic drug compounds. The type and 
concentration of the surfactant showing effect on droplet size of micro- or nano-
emulsions. Therefore, two important factors are hydrophilic-lipophilic balance (HLB) 
value and concentration of the surfactants [12]. The frequently utilized emulsifiers 
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include Polysorbate 20 (Tween 20), Polysorbate 80 (Tween 80), Sorbitan mono 
oleate (Span 80), Polyoxy-40-hydrogenated castor oil (Cremophor RH40), and 
Polyoxyethylated glycerides (Labrafil M 2125 Cs). In selection of a surfactant, safety 
is an important factor. Synthetic surfactants are considered to be less safe than the 
emulsifiers, which are obtained from natural origin. Moreover, these surfactants have 
a limited capacity for self-emulsification. Emulsifiers from natural sources are seldom 
employed for the formulation of SEDDS. Ionic surfactants are shown to be more 
harmful than non-ionic surfactants but may induce reversible improvements in 
intestinal lumen permeability. Normally, to form stable formulations, the surfactant 
concentration varies from 30-60% w/w [13].
2.2. Oils
The oil serves as among the most essential excipients in SEDDS formulation, as it 
not only solubilizes the required amount of lipophilic material or promotes self-
emulsification, but also improves the fraction of lipophilic drug transferred through 
the intestinal lymph system. It also improves secretion from the gastrointestinal tract 
(GIT) based on the molecular properties of the triglyceride [14]. Medium and long 
and chain triglyceride (MCT and LCT) oils of varying degrees of saturation have 
been used for the fabrication of self-emulsifying preparations [15]. Mostly the 
unmodified and raw forms of edible oils provide base as lipid vehicles, but the 
significant challenges are faced when it fails to dissolve large amounts of lipophilic 
drugs. Hydrolyzed or modified vegetable oils have made a significant contribution to 
the application of the systems. In the existence of a significant amount of non-ionic 
surfactants, such excipients produce good emulsification systems that are approved 
for oral administration [16, 17].
Most of the mono-, di-, and triglycerides and their mixtures in varying 
proportions, with or without the fatty acid esters of propylene glycol, are available 
commercially in the purified form. Both unsaturated and saturated fatty acids have 
been widely employed in the formulation of lipidic systems. However, the SEDDS in 
particular are comprised of saturated fatty acids such as caproic, caprylic, capric, 
lauric, and myristic acid. One can make the appropriate choice of these by 
examining their composition, potential utilities, physical state, and hydrophilic-
lipophilic balance (HLB) [13].
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2.3. Co-solvents
Relatively high concentrations (usually greater than 30% w/w) of surfactants are 
required for the development of optimum SEDDS, therefore the concentration of the 
surfactant may be decreased by the addition of the co-surfactant. This reduces the 
surface tension and creates a mixed micelle along with a surfactant, which gives 
more surface area. Also, it keeps the spontaneity of self-emulsification process. 
Ethanol, propylene glycol (PG) and polyethylene glycol (PEG) are few such 
examples [18]. 
Various studies on different kind of SEDDS along with their compositional 
account and outcome have been summarized in Table 2. The inclusion criteria of 
these studies are similarity in type of surfactant, co-surfactant used and dissimilarity 
in the type of developed formulations and in their applications. Katla and 
Veerabrahma developed losartan containing solid self-emulsifying drug delivery 
system (S-SEDDS) and altered it into liquid self-emulsifying drug delivery system (L-
SEDDS). It was observed that L-SEDDS exhibited better self-emulsification 
efficiency and thermodynamic stability. The in vivo study has confirmed the 
enhancement of oral bioavailability by 2.82 folds. The SEDDS showed stability for 
three months at room temperature [19].
Zupancic et al. prepared various SEDDS formulations including no lipids (NL-
SEDDS), short chain lipids (SC-SEDDS), medium chain lipids (MC-SEDDS), long 
chain lipids (LC-SEDDS) containing enoxaperin, a low molecular weight heperin 
(LMWH). The formulations were evaluated for drug release and mucous 
permeability. The MC-SEDDS and NL-SEDDS revealed good mucous permeability. 
The MC-SEDDS degraded in presence of pancreatic lipase whereas NL-SEDDS 
within 90 min showed good stability. The bioavailability of enoxaparin was found to 
be enhanced by 2-fold [20].
In another study, Zupancic et al. developed daptomycin (lipopeptide) 
containing SEDDS and performed in vitro digestion, permeability and enzyme 
degradation studies. The optimal formulation was found to be hydrolyzed within 90 
min by lipase and showed better mucous permeation along with protection by α-
chymotrypsin. The formulation demonstrated sustained drug release for not less than 
six hours. The study revealed that the payload of daptomycin has been enhanced by 
5-folds. Moreover, the result showed that SEDDS comprising 8% drug complex 
might be tested as a potential oral drug delivery device [21].
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Sandhu et al. developed tamoxifen (TMX) and neringenin (NG) containing 
SNEDDS formulation (TMX-NG-SNEDDS) for the treatment of breast cancer. 
Different combination of SNEDDS were prepared and evaluated by cell line study, 
drug release, pharmacokinetic study, and in vivo antitumor activity. The authors 
reported that the formulation showed good micelle forming capacity, drug release 
within 30 min and reduced percent of tumor burden [22].
Lee et al developed thirteen formulations of 5α-reductase inhibitor, dutasteride 
(DTS) loaded supersaturable-SEDDS (SS-SEDDS) for improving the oral absorption 
of DTS. A polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
copolymer, Soluplus® (precipitation inhibitor) was employed to develop SS-SEDDS 
by selecting DTS: SEDDS vehicle:Soluplus® in 1:67.6:10 w/v/w proportion. Under in 
vivo study, the SS-SEDDS preparation displayed 3.9- and 1.3-folds higher area 
under the curve (AUC) values in comparison to the drug suspension and SEDDS, 
respectively. The maximum plasma concentration of SS-SEDDS was found to be 
2.0- and 5.6-fold greater than SEDDS and drug suspension, respectively. High 
absorption of drug, pH dependent dissolution of formulation and 3.9-fold 
enhancement of bioavailability as compared to drug suspension was observed. The 
outcome suggested that the SS-SEDDS might be an effective tool to enhance the 
physicochemical property and oral absorption of 5α-reductase inhibitor [23]
3. Method of preparation of SEDDS
3.1. High pressure homogenizer
Nano-formulation is prepared under high pressure. The formation of fine emulsion 
depends upon the high shear stress applied. The droplet size can be explained by 
two theories i.e., cavitation and turbulence. This method can produce nanoemulsion 
of droplet size smaller than 100 nm. The droplet size of nanoemulsions produced by 
high pressure homogenizers depend on sample composition, homogenizer type, and 
homogenizer operating conditions such as energy intensity, time, and temperature. 
High-pressure homogenization is widely used to form food, pharmaceutical, and 
biotechnological ingredient nanoemulsions [24, 25].
3.2. High energy approach
The high energy approach requires high mechanical energy by which mixture of 
components like oil, surfactants and co- solvent are mixed to form nanoemulsion. 
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High energy methods are extensively used to formulate nanoemulsion [26]. High 
mechanical energy is used that provide strong disruptive forces, which break up 
large droplets to nano-sized droplets and produce nanoemulsions with high kinetic 
energy [27]. However, SNEDDS are based on the self-emulsification phenomenon 
and require low energy [28].
3.3. Micro-fluidization
The micro-fluidization method requires a device called Micro-Fluidizer. The positive 
displacement pump pushes the product to the interaction chamber. This system 
contains a small dr plet channel known as micro channel. The obtained product was 
sent through the micro channels to the impingements area, which produces very fine 
droplets of nanoemulsion. The mixture of oil phase and aqueous phase gets into the 
homogenizer, which yield course emulsion. It is further processed and forms 
homogeneous, stable, transparent nanoemulsion. 
3.4. Sonication method
The sonication method is the very useful method for the preparation of the SNEDDS. 
Ultrasonication is better than other high energy methods in terms of operation and 
cleaning. In ultrasonic emulsifications, ultrasonic waves provide cavitation forces that 
break the macroemulsion to nanoemulsion [29]. By using this method, the droplet 
size of the emulsion decreases and a nano-sized emulsion is obtained. The droplet 
size is reduced by the sonication mechanism [30]. 
4. Evaluation techniques of SEDDS
4.1. Droplet size analysis
The surfactant nature and concentration determine the size of the droplet [31]. 
Droplet size is critical and possesses key importance for self-emulsification as it 
determines the rate and extent of drug release followed by absorption. Low dilutions 
are preferred for accurate droplet size evaluation. However, Photon correlation 
spectroscopy is helpful for determining the droplet size of the emulsion, especially, 
when the properties of the emulsion do not change upon infinite aqueous dilution 
[32, 33].
Page 8 of 53





























































For Peer Review Only
4.2. Emulsification time and Dispersibility test
The rate of self-emulsification is usually determined by keeping self-emulsifying 
formulations (pre-concentrate) in a capsule and it to a sufficient amount of water or 
bio-relevant media. The rate of dispersion is determined by visually. Light 
microscopy is used to observe the process of self-emulsification. The USP XXII 
dissolution apparatus can be used for determining the efficiency of oral 
nanoemulsion or microemulsion. In this case, sample formulation (1 mL) is mixed 
with water (500 mL) at temperature of 37±1°C. For continuous agitation stainless 
steel dissolution paddle has been utilized with the stirring speed 100 rpm and the 
time is noted for the emulsion formation. The precipitation and the phase separation 
of resultant mixture are checked at different time intervals (2, 4, 6, 8, 12, 24 hrs). 
Grading system, used for evaluating the in vitro performance [34] is given below:
Grade A: Rapidly forming nanoemulsion, which takes time less than 1 min and gives 
bluish colored clear solution.
Grade B: Rapidly develop a nanoemulsion with a bluish-white color.
Grade C: Develop fine milky nanoemulsion within 2 min.
Grade D: Formation of dull, grayish colored emulsion with oily appearance that 
emulsifies gradually and requires more than 2 min.
Grade E: Weak emulsification resulting in large oil globules on the surface.
The time for emulsification at room temperature is indicated as self-
emulsification time for the formulation. Pouton et al. analyzed the emulsification 
capacity of the different compositions of the Tween 85 and MCT systems via a 
rotating paddle to facilitate emulsification in a crude nephelometer. It assisted in the 
measurement of the time taken for emulsification. Once the emulsification was 
complete, photon correlation spectroscopy (also known as quasi-elastic light 
scattering or dynamic light scattering) technique was used for particle sizing. The 
self-emulsified systems were compared with that of homogenized systems. Light 
microscopy technique was used to observe the self-emulsification process [35].
4.3. Test for transmittance/turbidity measurement
Turbidimeters are used to establish, whether the dispersion attains equilibrium 
quickly and in a reliable time frame [36]. Orbeco-Helle turbidity meter and Hach 
turbidity meter have been used frequently [37, 38]. A dissolution apparatus is 
connected to the turbidity meter. At every 15 sec, optical clarity is observed to 
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determine clarity of micro or nanoemulsion formed. Turbidity can also be measured 
in terms of spectroscopic characterization of optical clarity by taking the absorbance 
of suitably diluted aqueous dispersion at 400 nm [39].
4.4. Transmission electron microscopy
The SNEDDS sample was introduced inside TEM for visual observation [40]. A drop 
of SNEDDS sample was kept on the copper grid and 1% w/v phosphotungistic acid 
solution was added on the grid and kept in room temperature for 5 min. The image 
was observed with the help of TEM at an accelerated voltage of 100 kV [41].
4.5. Liquefaction time
This study is performed to calculate time needed by solid SEDDS formulation to melt 
in vivo without agitation in simulated gastric fluid (SGF) [42]. The formulation is 
wrapped in a transparent polyethylene film and attached to a thermometer bulb, 
which is dipped in a round bottom flask filled with SGF without pepsin maintained at 
37±1oC.
4.6. Dynamic dispersion study
This study is used to determine if drug was precipitated during dispersion, and if so, 
what proportion of the dose was precipitated and at what rate [43]. Mohsin et al. 
performed a dispersion study by dissolving fenofibrate in each SEDDS/SNEDDS at 
80% saturation level based on its equilibrium solubility studies in the relevant 
anhydrous formulation. One gram of each formulation was dropped into 100 mL of 
water in a glass jar and kept in a dry heat incubator at 37°C for 24 h. During this 24 h 
period, 1 mL of the dispersed sample from each container was withdrawn 
periodically (0-24 h) and centrifuged at 2,500× g. A 100 µL aliquot of the resulting 
clear supernatant was assayed by the UHPLC method. The dispersion studies 
confirmed that the mixed glycerides can retain a high percentage of drugs in solution 
for 24 h in the intestinal media [44].
4.7. Lipolysis test
In vitro lipolysis model for lipid digestion have been increasingly used as tools to 
assist in the design of self-emulsifying lipid-based formulations to enhance the oral 
bioavailability of poorly water-soluble drugs. During in vitro lipolysis studies, the data 
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generated from the pH-stat can be used to quantify the rate and extent of lipolysis, 
and more importantly, the products of lipolysis can be examined after completion of 
the reaction, to determine the fate of the drug; whether it is solubilized or precipitated 
[45].
5. Types of SEDDS in drug delivery
5.1. Self-emulsifying capsules
The basic form of SEDDS is liquid and can be encapsulated in soft/hard gelatin 
capsules. After the administration of capsules containing conventional liquid self-
emulsifying (SE) preparations, the droplets of microemulsion have been formed and 
dispersed in the GIT and reached to the site of absorption. If microemulsion shows 
irreversible phase separation, then there will be no improvement in drug absorption. 
For managing this problem, sodium dodecyl sulfate has been added to the SE 
formulation. This helped in creating and sustaining the supersaturated form under in 
vivo condition. Such formulations contain less surfactant; hence reduce any side 
effects on GIT [46].
5.2. Solid SEDDS 
The SEDDS are generally designed in the liquid state, so it has to be administered 
by soft gelatin capsules, which leads to greater manufacturing costs, lesser 
portability, lower drug loading and poor stability. For overcoming these problems 
solid SEDDS(S-SEDDS) has been developed, which shows greater advantages over 
conventional SEDDS i.e. enhancement of solubility, bioavailability, reduced 
production cost, improved stability and patient complains. For the fabrication of S-
SEDDS, liquid or semisolid ingredients are incorporated into powders by various 
solidification methods like melt extrusion, melt granulation, nanoparticle technology 
and spray drying. Other techniques can also be employed for the development of S-
SEDDS such as adsorption of liquid formulation onto the solid carriers like colloidal 
silica, hydroxypropyl methyl cellulose (HPMC) and microcrystalline cellulose (MCC) 
[47-52]. 
5.3. Self-emulsifying controlled/sustained-release pellets
Pellets are more advantageous then other conventional solid dosage forms. These 
are easy to fabricate, lower GI irritations, intra- and inter-subject variability in plasma 
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profile. Glyceryl benzoate and glyceryl palmito stearate are mostly preferred for the 
development of sustained release pellets e.g. SE nitrendipine pellets and 
progesterone pellets [53]. 
5.4. Dry emulsion
It is mostly oil in a water emulsion converted into solid by various methods like 
carrier adsorption, spray drying and freeze drying. Before use, dry emulsions are 
dispersed in water. Emulsification of these powders occurs when it gets exposed to 
an aqueous media. The use of toxic organic solvents can be avoided by this 
technology and it also removes the stability issues related to contamination by 
microbes, phase sepa ation and creaming. For developing these types of 
formulations, MCTs are mostly used as non-aqueous phase [54, 55]. 
5.5. Self-emulsifying suppositories
The SE-Suppositories not only increase the GI adsorption but also improve the 
vaginal and rectal absorption e.g. the indomethacin given orally does not achieve the 
therapeutic plasma concentration but by vaginal or rectal route it achieves 
satisfactory therapeutic level [56]. 
5.6. Self-emulsifying beads
In the development of this system, the number of excipients used was very less. 
Solvent evaporation method was mostly used for depositing the SE system onto the 
microporous polystyrene beads, which consist of complex internal void structures 
and prepared by copolymerization of divinyl benzene and monomer, styrene. These 
were found to be chemically inert, biocompatible and stable over a broad range of 
temperature, pH and humidity [57].
5.7. Self-emulsifying nanoparticles
Nanoparticles (NPs) can be prepared by various methods including sonication 
method and solvent injection method. In later technique [58], the molten lipid, drug 
and surfactant are injected drop wise to the non-solvent system. After this, larger 
particles were separated by filtration and the remaining filtrate is dried up to obtain 
the NPs [59].
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6. Biomedical applications of SEDDS
Since the earth evolution, naturally occurring compounds are a great source of 
medicinal principles. These plant constituents are facing many hurdles in their 
delivery in the body like low bioavailability, low solubility, and fast release. The 
SEDDS has attracted more consideration due to better oral bioavailability of drug 
allowing dose reduction and enhancing their physio-chemical features [60]. Some of 
the SEDDS mediated drugs with improved oral solubility and bioavailability 
discussed below and summarized in Table 3. The inclusion criteria of the mentioned 
studies are the drugs showing poor solubility, less bioavailability and used for 
different applications.
6.1. Anti-coagulant activity
Mundada and Sawant developed SMEDDS using P-glycoprotein (P-gp) modulator 
excipient to elevate the systemic availability of dabigatran etexilate (DE). 
Researchers have taken Transcutol HP as co-surfactant, Cremophor EL as 
surfactant and Capmul MCM C8 as oil phase for the fabrication of SMEDDS. On the 
basis of MTT assay on Coco-2 cells, the DE-SMEDDS was found to be non-cytotoxic 
and safe. In addition, the AUC0→t of DE from DE-SMEDDS formulation showed 2.5 
times higher and relative bioavailability was improved by 3.36 times more than that 
from drug suspension on oral administration to rats. The DE-SMEDDS demonstrated 
higher anticoagulant activity than product suspension [61].
6.2. Antimicrobial activity
Jalil et al. fabricated a SEDDS system containing monododecylamide-EDTA 
(alkyl-EDTA) and chlorhexidine (CX), which shows enhancement of antimicrobial 
properties. SEDDS comprising of Tween 80 (17%), Captex 300 (20%), DMSO 
(18%), and Cremophor EL (45%) were incorporated with alkyl-EDTA (FA) (3% m/v). 
Further, formulations have been developed by selecting 1% m/v CX (FA-CX1%) and 
1.5% m/v alkyl-EDTA (FA-ED1.5%) individually and in combination (FA-CX1% andFA-
ED1.5%). The biocompatibility of SEDDS was evaluated by Resazurin assay. More 
than 85% cells were found to be viable after 4 hr. Antimicrobial properties were 
analyzed by Escherichia coli model. The outcomes of this study revealed that 
combination of (FA-CX1% and FA-ED1.5%) demonstrated 34.3- and 12.9-fold 
improved antimicrobial effect as compared to the 1% of FA-CX and 1.5% of FA-ED, 
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respectively. The researchers concluded that combination of FA-CX1% and FA-
ED1.5% in SEDDS system improved the antimicrobial activity [62].
Zaichik et al formulated vancomycin loaded SMEDDS with enhanced 
intestinal mucosa permeating properties and increased absorption of orally 
administered drug by enhancing the drug lipophilicity via HIP with 
cetyltrimethylammonium bromide. The formulation exhibited better (4-8-fold) ability to 
permeate porcine intestinal mucosal barrier. HIP with SEDDS is found to be 
promising for oral antibiotic delivery [63].
Zaichik et al developed ciprofloxacin, a fluoroquinolone antibiotic loaded 
SEDDS for revealing antimicrobial activity and extremely mucus permeating 
properties through in vitro models. Furthermore, the antimicrobial activity of 
formulation (F11-ciprofloxacin)containing 10% oleic acid as lipid phase, 20% 
Labrasol, 30% Labrafil M1944 CS, 25%Cremophore EL as surfactants, and 15% 
Transcutol as co-surfactant against S. aureus was found to be higher in contrast of 
free drug. The outcome of the study suggested that SEDDS formulations might be 
considered as an effective delivery system for treating pulmonary infections 
convoyed by mucus dysfunction [64].
6.3. Antihyperlipidemic activity
Ahsan et al. fabricated S-SNEDDS of rosuvastatin for increasing the in vitro 
drug release and analyzed its anti-hyperlipidemic activity. After 14thday of treatment 
the results of antihyperlipidemic study showed that cholesterol level was found to be 
decreased to 33.47% followed by atherogenic index 81.28% and triglycerides 
40.77%, however high-density lipoprotein (HDL) was increased to 118.43% [65].
6.4. Antioxidant activity
The SS-SMEDDS were developed by Zheng et al to increase the solubility of 
ellagic acid. The in vivo and in vitro antioxidant activity of SS-SMEDDS loaded with 
ellagic acid have been found considerably higher than that of pure ellagic acid at the 
same concentration [66].
Balakrishnan et al composed SEDDS for oral administration of a lipophilic 
drug, Coenzyme Q10 (CoQ10) to improve its bioavailability and solubility. The 
optimized SEDDS formulation consisting of 25% v/v Labrafil M 1944 CS, 65% v/v 
Labrasol and 10% v/v Capryol 90 and exhibited least mean droplet size of 240 nm. 
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The SEDDS formulation has significantly improved the Cmax and AUC of CoQ10 than 
powder form (P < 0.05). Thus, SEDDS can be a potential oral dosage form for 
increasing the bioavailability of CoQ10 [67].
Mamadou et al formulated and studied the capability of SEDDS to increase 
permeation of resveratrol across the intestine of rat and control its pre-systemic 
metabolism. Jejunal absorptive transepithelial fluxes (Jms) and pre-systemic 
metabolization of resveratrol released from semisolid and L-SEDDS formulations 
were analyzed. The absorptive fluxes from the semisolid nanoemulsions and liquid 
nanoemulsion were found to be 20.5±3.1 and 28.9±2.9 μg h-1cm-2, respectively. 
These fluxes were f und to be improved as compared to an ethanolic control 
solution (Jms = 3.4±0.3 μg h-1 cm-2; p<0.05). The results revealed that o/w 
nanoemulsion with medium-chain lipids could be a possible preparation for improved 
oral delivery of resveratrol [68].
6.5. Anticancer activity
The SEDDS have been broadly employed for chemotherapeutic agents to 
improve their oral bioavailability. Table 4 enlists the different types of anticancer 
drugs/active constituents and their pharmacokinetic effects [69-76].
Cadete et al. used a self-emulsification process for formulating docetaxel 
(DTX)-loaded nanocapsules of hyaluronic acid (HA) without the use of heat and 
organic solvent. Researchers used A549 lung cancer cells for in vitro studies and 
found effective intracellular delivery of DTX, whereas the blank nanocapsules 
showed a very low cytotoxicity [77].
Timur and co-workers fabricated doxorubicin (DOX) and LyP-1 peptide 
containing SMEDDS for evaluating their efficacy in breast cancer. The result showed 
significantly enhanced in vitro cytotoxicity in p32-expressing breast cancer cells 
(MDA-MB-231 and 4T1), however, metastasis and tumor growth were significantly 
reduced on intraperitoneal administration of DOX-LyP-1 SMEDDS [78].
6.6. Chronic heart failure
Jiang et al prepared and analyzed SEDDS to determine the improved 
preventive activity of curcuminoids on chronic heart failure in rats. Different 
pathological changes were analyzed in model (coronary artery ligation) group 
comparative to sham group. After treatment using curcuminoids SEDDS or 
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suspension, these changes were inverted related to model group. In the meantime, 
the SEDDS (ameliorative effect) based curcuminoids was evidently well in its activity 
than curcuminoids suspension as witnessed by pharmacodynamic studies [79].
6.7. Antifungal activity
Kontogiannidou et al fabricated Amphotericin B (AmB) containing N-trimethyl 
chitosan chloride (TMC) based SNEDDS and analyzed its transportation ability 
through GIT. Application of this developed formulation in intestinal epithelium (Caco-
2 monolayer) demonstrated its ability to promote the temporary opening of tight 
junction, duly assisted by TMC. The outcomes of this study suggested that 
combination of SNEEDS and TMC enhanced the permeation ability to enable oral 
delivery of AmB [80].
Alhakamy et al formulated Bifonazole (BF)-loaded SNEDDS (BF-SNEDDS) 
using the mixture design and analyzed the antifungal activity against Candida 
albicans. Researchers found 26±3 mm of zone of inhibition, which indicated 
enhanced the antifungal activity. So SNEDDS can be used as a promising system 
for transdermal delivery of BF [81].
Elbahwy et al developed mucoadhesive SEDDS with extended ocular 
residence time of poorly water-soluble drug, Econazole. The droplet size of SEDDS 
was found to be<100 nm with polydispersity index <0.3. The SEDDS formulation 
revealed 2.5-fold greater mucoadhesive activity than plain SEDDS and sustained 
drug release for 8 hr without noticeable corneal adverse effect in 0.5% m/v 
concentration. Thus, the formulated mucoadhesive SEDDS was suggested as an 
effective ocular delivery system for lipophilic drug [82].
6.8.  Antidiabetic activity
Agarwal and co-workers developed SMEDDS using extract of Lagerstroemia 
speciose (SEL) leaves (SEL-SMEDDS) and evaluated its pharmacodynamic 
performance as antidiabetic activity. At 50 mg/kg dose, the SEL-SMEDDS 
formulation demonstrated a higher reduction in blood glucose level (BGL) as 
compared to the plain SEL formulation, however, this reduction was found to be 
more significant at dose of 100 mg/kg on 15th day of study [83].
El-Bagory and co-workers prepared dapagliflozin loaded SNEDDS and 
converted it into S-SNEDDS using Avicel pH-101as a biocompatible adsorbent. In 
Page 16 of 53





























































For Peer Review Only
diabetic albino rats, the researchers found higher hypoglycemic activity of 
dapagliflozin containing S-SNEDDS and SNEDDS as compared to the plain drug. 
This study proposed that S-SNEDDS could serve as an efficient nanovehicle for the 
oral delivery of dapagliflozin for improved diabetes mellitus management [84].
In another study Agrawal et al developed L-SEDDS of glipizide and converted 
into S-SEDDS with adsorbent, Syloid® 244 FP. The optimized formulation of L-
SEDDS comprised of phosphatidylcholine, Transcutol P and Tween 80. The BGL 
has been effectively regulated using S-SEDDS as compared to the pure drug in vivo 
[85].
6.9. Hepatoprotective activity
Ogino et al employed SS-SEDDSto increase the nutraceutical characteristics 
of ginger extract (GE). The SEDDS of GE comprised of glycerin, lysolecithin and 
MCT. The formulations enhanced the dissolution property of GE by creating fine 
micelles of 110 nm size. On oral administration of GE, the relative bioavailability of 8-
gingerol and 6-gingerol in SS-SEDDS/GE-treated rat group was found to be 3-fold 
greater than GE-treated group. The frequent oral administration of SS-SEDDS/GE in 
dose of 100 mgGE/kg showed hepatoprotective action in carbon tetrachloride-
induced hepatotoxicity in rat [86].
6.10. Benign prostatic hyperplasia
Alhakamy et al. formulated SNEDDS formulation by taking tadalafil (TDL) as 
drug andpumpkin seed oil (PSO). The zeta potential and average globule size of 
TDL-PSO were found to be7.86 ± 1.21 mV and 204.8 ± 18.76 nm, respectively. TDL-
PSO showed reduced prostate index (36.71%) and prostate weight (35.51%) as 
compared to that of the testosterone. As per pharmacodynamic study the 
concentration of TDL increased 2.3-fold in TDL-PSO system in contrast to the plain 
TDL. The outcomes of this study concluded that TDL-PSO SNEDDS could enhance 
the effectiveness of TDL in benign prostatic hyperplasia management [87].
6.11. Hypertension
Prajapat et al fabricated SMEDDS for a BCS class II drug, nimodipine. Firstly, 
L-SMEDDS was fabricated by employing simplex lattice matrix design then the 
optimized formulation was converted into S-SMEDDS using different adsorbents. 
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The pharmacodynamic study revealed that optimized S-SMEDDS decreased the 
blood pressure (BP) in rats [88].
6.12. Cardiovascular activity
Yadava et al developed a stabilized hydrogel system comprising of SEDDS to 
enhance the bioavailability of HMG CoA reductase inhibitor, lovastatin. The AUC0–5 
of formulated hydrogel was found as 2.27-fold greater than free drug. Furthermore, 
the maximum concentration (Cmax) was increased around 1.42-fold [89].
7. Marketed appr aches of SEDDS
Figure 3 presents some of the SEDDS products available in the market. It is 
obvious that the SEDDS is a commercially viable system for BCS Class II and IV 
drugs [90].
8. Patent perspective of SEDDS: Recent updates
Various methods have been developed or patented for the fabrication of drug 
or therapeutics containing SEDDS. A description of the SEDDS related patents has 
been presented in Table 5 especially for the period of 1999-2020 [91-130]. 
Wang et al 2020 invented a fabrication method for self-microemulsionof β-
elemene. Proposed fabrication method has utilized3-12 parts of β-elemene, 6 parts 
of ethyl oleate, 6-10 parts of a co-surfactant (PEG400 and/or 1, 2-propylene glycol), 
and 10-15 parts of a surfactant (polyoxyethylene 40 hydrogenated castor oil and/or 
Tween 80). Results have shown that ethyl oleate, polyoxyethylene 40 hydrogenated 
castor oil and 1, 2-propylene glycol have better compatibility and can be excellently 
dissolved as well as rapidly emulsified in different proportions. The emulsifying 
potential of Tween 80 is low, so polyoxyethylene 40 hydrogenated castor oil is used 
as a surfactant and PEG400 is selected as a co-surfactant [91].
Zhang et al 2020 developed a solid self-microencapsulated microcapsule, 
which uses combination of astaxanthin and quercetin so that the conventional single-
carrying astaxanthin mechanism can be disrupted and quercetin can inhibit the 
external discharge effect of P-glycoprotein (P-gp) to the drug. This action of drug 
metabolizedCYP3A4 enzyme, inhibited P-gp and improved bioavailability. The 
findings of this invention concluded that proposed system can improve the stability, 
dissolution rate and bioavailability of the drug [92].
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Xue et al 2020 invented a self-emulsification system by using water-based 
epoxy resin as curing agent. Mentioned system contains amino silicone oil (1-10 
parts), epoxy resin (20-30 parts),reaction auxiliary agent (0.01-5 parts), solvent (120-
250 parts) and end-capping agent (1-10) parts. This system can provide outstanding 
curing efficiency on various water-based epoxy resins. Further, the epoxy resin film 
has reasonable durability including heat and chemical resistance, electrical 
insulation, and hydrophobicity [93].
Chen et al 2019 developed a type of injectable self-emulsifying drug emulsion 
and disclosed its fabrication process along with application. Mentioned system uses 
surfactants with high emulsibility and low dose so that it becomes less irritant to body 
tissue. The outcomes have revealed that if the pre-mixing liquor of emulsion is less 
than 40%, then the corresponding dosage type is oil-in-water (o/w) emulsion, 
however, if it is more than 65%, then the subsequent dosage form is water-in-oil 
(w/o) emulsion. The inventors have been claimed that drugs accounting 40-60% 
(ideally 50%) are appropriate for slow release and can help to attain higher stability 
[94]. 
Liu et al 2019 patented an invention of chlorogenic acid self-emulsifying 
composition and its application. Inventors prepared the composition by taking 
chlorogenic acid, a matrix material compound, emulsifier and oily phase and 
disclosed that for avoiding lamination or solidification, formulation should be placed 
at room temperature. Above composition could be administered as orally, 
percutaneously, nebulized inhalation system and mucosal delivery. The formulation 
was found effective for antiviral, antitumor and anti-inflammatory treatment [95].
Jung et al 2019 developed SMEDDS containing ticagrelor for enhancing the 
bioavailability by alleviating poor solubility and low intestinal permeability of 
ticagrelor. Furthermore, the composition of ticagrelor enhanced the efficacy of active 
components and reduced their amount [97].
Christopher et al 2019 disclosed SEDDs for oral administration of water-
insoluble cannabinoids. This mentioned cannabinoid-loaded SEDDS preparation 
permitted the oral administration of cannabinoids to achieve their higher oral 
bioavailability to control or prevent a disease, condition or symptom of the disease 
[100].
Xiong et al 2018 patented a research of sanguisorbin containing SEDDS. 
Inventors prepared the formulation by taking large amount of sanguisorbin along with 
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0.05-0.25% of oil phase, 0.45-0.65% of surfactant and 0.1-0.3% of co-surfactant. 
The goal of the discovery was to resolve the prior art deficiency in order to provide a 
kind of SE sanguisorbin drug. The inventors found significantly improved solubility 
and dissolution rate of sanguisorbin loaded SEDDS [104].
Zhang et al 2018 fabricated a kind of osthole SEDDS by taking 0.1-10% of 
osthole (an active ingredient isolated from extract of fruit cnidii, along with 5-45% of 
surfactant, 25-55% of oil phase and co-surfactant as an auxiliary material. The 
inventors found that osthole SMEDDS can attain 90% or more dissolution in 45 min 
as compared to osthole bulk pharmaceutical chemicals (less than 40% in 180min). 
The dissolubility of the product enhanced osthole infiltration and increased bio-use of 
ostholes in the human body [103].
Jianget al 2018 patented an invention of asarone encapsulated SEDDS. This 
system was made up of asarone, oil phase (10-70%), surfactant (30-80%) and co-
surfactant (0-30%). The inventors claimed that above prepared system significantly 
enhanced the drug bioavailability, increased the stability and improved the drug-
eluting rate [106].
Hustvedt et al 2017 patented a formulation containing fatty acid like 
eicosapentaenoic, docosahexaenoic acid etc., free fatty acid, antioxidants, and 
various surfactants. The pre-concentrates are able to form SEDDS, SNEDDS or 
SMEDDS in aqueous solution. It can be given in the form of tablet or capsule for the 
treatment of any health-related problem like visual function, cardiovascular function, 
insulin action, immune function etc [108]. 
Chow et al 2016 disclosed about the formulation containing mebendazole, a 
benzimidazole derivative, oil, surfactant, dipolar aprotic solvent and co-solvent 
prepared by micro-emulsion and co-solvency method. The formulation increased the 
bioavailability by improving the solubility and drug release by 130-fold as compared 
to unformulated suspension. The developed formulations demonstrated high efficacy 
in the treatment of hyper-proliferative diseases and cancer [110].
Nahat et al 2015 disclosed the pharmaceutical composition incorporating 
rhein or diacerein and other excipients. The invention claimed that 50 mg of 
diacerein was found to be bioequivalent to marketed product, Art 50®and reduced 
the side effect i.e. soft stool. The SS-SEDDS was prepared, which lowered the side 
effects of surfactant and resulted in reduction in gastrointestinal side effects [112].
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Liu et al 2014 developed SEDDS based novel delivery system, which 
composed of 1-65% butylphthalide and 10-65% other essential ingredients. 
Inventors claimed that with the increase in surfactant concentration, microemulsion 
was formed inside GIT. The SEDDS was first emulsified than dispersed throughout 
the GIT and resulted in lowering of mucosal irritation. Thus, the nano-or micro-sized 
particles crossed the membrane and oil droplets moved into the blood circulation 
leading to increase in bioavailability and stability of drug [115].
Khan et al 2014 disclosed about the eutectic SNEDDS formulation containing 
CoQ10, essential oil, copolymers and co-surfactants. The semisolid formulation was 
developed and introduced inside the soft gelatin or hard gelatin capsule. It melted 
down at body temperature losing consistency from semisolid to liquid and dispersed 
to form nanosized droplets [116].
Legen et al 2013 dev loped SMEDDS with the help of polysorbate 80 to 
improve the solubility of poorly soluble substance. Further, it has overcome the 
problem related to the liquid or semisolid administration by delivering the substance 
in hard or soft gelatin capsule [117].
Lin et al 2012 prepared SMEDDS, which comprised of CoQ10,poorly soluble 
excipients like hydrophilic surfactant with HLB value more than 12, hydrophobic co-
surfactant having HLB less than 8 and hydrophobic solvent with co-surfactant and 
surfactant. The ratio of hydrophilic surfactant to lipophilic co-surfactant was selected 
in the range from 30:1 to 3:1.Inventors demonstrated increased loading capacity, 
with improved stability up to 80 days and enhanced dissolution near to 100% [118].
Kohli et al 2011 fabricated SNEDDS containing curcumin. Precipitation of 
curcumin by surfactant is a common problem in curcumin-based formulations, 
however, this problem was not observed in case of developed SNEDDS. The 
formulation showed good loading capacity, enhanced bioavailability and better 
stability [119].
Holmerg et al 2010 prepared a formulation having nitrogen oxide (NO) 
releasing non-steroidal anti-inflammatory drug (NSAID), phospholipids, surfactants, 
semisolid fat or oil and short chain alcohol. The formulation was in pre-concentrate 
form, which could be enclosed in capsules, lozenges or chewable pills at the time of 
administration. On contact with gastric fluid pre-concentrate converted into o/w 
emulsion and it could be a better solution for preventing problems related to stomach 
[120].
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Simonnet et al 2001 developed a nanoemulsion containing anionic surfactant, 
aqueous phase and oily phase belonging to oxyethylenated derivative and 
phosphoric acid fatty ester. The globule of oil having molecular weight more than 400 
dalton showed the size less than 100nm. The weight ratio of the oil phase to the 
aqueous phase varies from 2 to 10. This invention explained about the method of 
preparation, its good transparency and uses of nanoemulsionin dermatological, 
ophthalmic, cosmetics and topical pharmaceuticals [128]. 
Mulye et al 2000 developed a formulation, which contained cyclosporine, non-
ionic surfactant with HLB value more than 10 and fatty acid with carbon chain C6 to 
C22. This system was found to overcome the problems related to solubility and 
dissolution with advantages of high drug load and patient compliance because of 
reduction in size of the dosage form. Leakage and brittleness could also be 
prevented by administrating it in soft or hard gelatin capsule [129].
In another study Bhalani et al 1999 prepared a formulation possessing 
cyclosporine, a water insoluble drug having problem related to taste and instability. 
For controlling such problems polar lipid SEDDS (PLSEDDS) was developed by 
adding cyclosporine with polar lipid and surfactant, which in presence of aqueous 
medium formed emulsion with globule size less than 50 nm. The PLSEDDS 
demonstrated the advantage of self-stability of formulation, no need of hydrophilic 
co-solvent or aluminum blister packaging [130].
9. Conclusion
Based on the various published studies, it can be concluded that SEDDS can 
be an appropriate carrier for the delivery of lipophilic substances with a minimum 
concentration of surfactant, a high drug loading potential and the necessary dilution 
can be obtained without drug precipitation. The SEDDS can be used for the 
development of the formulations of drug/bioactive with poor aqueous stability. 
Further, this technique can be explored for the development of a formulation with 
prolonged drug release by introducing appropriate polymer in composition. The 
advancement of this technology would give rise to a new application in the area of 
drug delivery. SEDDS has been shown to be essentially effective in enhancing oral 
bioavailability of lipophilic products.
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10. Expert opinion
Conventionally, drugs which are clinically magnificent and significant have 
always been difficult to handle, owing to its poor aqueous solubility or permeability 
which leads to lower therapeutic response (causing multiple dose regimen; also may 
lead to toxicity) and poor bioavailability has automatically reduced the chance of any 
drug to come to the market claiming it to be therapeutically safe and efficacious. 
Therefore, converting a drug in such a formulation which would not only reduce the 
dosing frequency, but also ensure to reduce the dose with maximized efficacy is an 
art and a challenge for formulation scientists. Approximately 40% of active 
pharmaceuticals are poorly water soluble. Lipid-based drug delivery systems in 
general and SEDDS in particular has great potential for enhancing solubilityand 
bioavailability of poorly water-soluble drugs. Since this ability has been recognized 
for almost two decades, the full impact of SNEDDS and its elements on the handling 
of these issues has been acknowledged in recent years.
Research articles and patents in various countries report many of the 
application and fabrication techniques of SEDDS. We have incorporated the latest 
patents focusing on the composition, classification and systemic optimization 
techniques of SEDDS. This will open the way for rapid advancement in 
pharmaceutical research as well as patents on SEDDS technology. The great 
interest in fabrication of SEDDS is to be a specific viable strategy for solving the 
problem with low oral bioavailability of hydrophobic drugs. Currently, oral SEDDS 
has received a lot of attention as a remedy to solve issues related to intra-and inter-
subject heterogeneity, shortage of dose proportionality of hydrophobic drugs, and 
poor oral bioavailability. Some significant in vitro features like zeta potential, 
oil/surfactant ratio, droplet size, emulsion polarity and surfactant concentration play 
key roles in the oral absorption of SEDDS containing drug. It can be administered 
orally as a hard-gel capsule (HGC) or soft-gel capsule (SGC) and also boosts the 
bioavailability of drug to maximize solubility and reduces gastric discomfort. After the 
administration of formulation, drug remains trapped in the oily droplets (within the 
droplet or in the film of the surfactant at the interface) of the emulsion formed during 
the self-emulsification process in the GIT. It is also a bit troubling to claim that the 
medication is being extracted from SMEDDS, it is more correct to say that it diffuses 
into the GIT media from oily droplets and in reality the mixture is established 
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between the substance absorbed in oily droplets and the outer distributed media 
(e.g. GIT fluids).
In addition to enhancing the solubility of poorly soluble drugs, SEDDS also 
improves the bioavailability of drugs through a number of other possible pathways, 
such as inhibiting P-gp efflux, resistance to metabolism by cytochrome P450 family 
enzymes in GIT and liver, as well as bypassing the hepatic first-pass effect.
A significant growth in both published research papers and patents in the area 
of SEDDS clearly demonstrates that it is an innovative delivery method for safe and 
selective distribution of drugs and other bioactives. The SEDDS can be developed 
by high pressure homogenization, high energy approach, sonication and micro-
fluidization techniques. However, these approaches yield SEDDS of different size 
and distribution. One needs to be careful when choosing a technique. In general, 
SEDDS are composed of oil, surfactant, co-surfactant and water. However, the 
choice of ingredients can influence various features including size, shape, solubility 
of drug, polydispersity, in vitro and in vivo drug release from SEDDS. Such 
specifications should also be carefully optimized for maximum efficacy of the 
fabricated formulations. 
The SEDDS as a drug carrier has been tested for a wide range of applications 
including enhancement of oral bioavailability and solubility of drugs with low aqueous 
solubility. From the literature review, it is very obvious that patents are coming from 
every corner of the world in almost all directions of drug delivery utilizing SEDDS as 
one of the choices among drug carrier options. Hence more modified version of 
SEDDS or simplified and industry-friendly fabrication techniques are warranted in 
near future.
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Figure Legends
Figure 1. Ishikawa fishbone diagram depicting different fabrication techniques, types, 
characterization process and biomedical applications of SEDDS
Figure 2. Merits and demerits of SEDDS
Figure 3. Some marketed products of SEDDS
Table Legends
Table 1. Comparative features of SEDDS, SMEDDS and SNEDDS
Table 2. Tabular presentation of different kind of SEDDS along with their 
compositional account and outcome
Table 3. SEDDS mediated drugs with improved oral solubility and bioavailability
Table 4. Different anticancer drug containing SEDDS and its pharmacokinetic action
Table 5. Description of SEDDS related patents especially for the period of 1999-
2020 [91-130]
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Table 1. Comparative features of SEDDS, SMEDDS and SNEDDS
Features SEDDS SMEDDS SNEDDS
Appearance Turbid Optically clear Optically clear
Size >300 nm 100-250 nm <100 nm
Concentration of surfactant 30–40% 40–80% 40–80%
Concentration of oil 40–80% >20% >20%
HLB value of surfactant <12 >12 >12
Category as per Lipid formulation classification 
system 
Type II Type IIIB Type IIIB
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Table 2. Tabular presentation of different kind of SEDDS along with their compositional account and outcome 
Type of 
SEDDS





Losartan, Labrasol, Labrafil 
M1944 CS, Lauroglycol 90, 
Labrafaclipophile WL1349, 
Transcutol P, Labrafil 
M2125, Cremophore, 
Campul, Tween 80, Oleic 
acid, Mannitol, 
Neusilinsylysia, Stearyl 







The study was performed 
in male wister rat. Losartan 
suspension was taken as 
control and S-SMED-N 
(Neusilin) as test. 
Pharmacokinetic 
parameters like Cmax, Tmax, 
AUCtotaletc were 
determined using Kinetica 
software.
The Cmax and AUCtotal were 
found to be 7.79±0.54 μg/mL 
and 39.57±5.31 μg/ml/hr, 
respectively. These values were 
statistically evaluated. The 
values were observed to be 
much higher than the losartan 
suspension levels. It showed 
2.82-fold increase in 
bioavailability as compared to 
losartan suspension.
[19]
SEDDS Enoxaparin, Float-a-lyse, 
Captex 8000, CapmulPG-8 
EP/NF, Peceol, Labrafil M 
1944 CS, Maisine, Labrasol, 
Transcutol HP, Mygliol 840, 
Cremophore, Triacetin, 
Propylene glycol, Sesame oil, 
Cetrimonium bromide, 
Dodecylamine hydrochloride, 
Olive oil, Benzalkonium 
chloride, Fluorescein 
daiacetate, Lipase, Bile salts 
Azure hydrochloride, Sodium 
deoxycholate and Sodium 
cholate in 1:1 ratio
The droplet sizes 
of LC (Long 
chain lipids) 10, 
MC (Medium 
chain lipids) 10 
and NL (No 
lipids) 9 were 





The PDI value of 
all was found in 
between 0.31-
0.52.
In vivo research was 
conducted in 6 male 
Sprague- dawley rat 
groups, On  group was 
treated with enoxaparin 
injection and others with 
oral administration. The 




There is an increase in 2-fold of 
anti-Xa activity of oral 
enoxaparin as compared to 
enoxaparin aqueous solution 
Hence, the absolute 
bioavailability was found to be 
2.25% and 2.02%, respectively.
[20]
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SEDDS Daptomycin, Capmul MCM 
EP, Dermofeel MCT, 









36±5 - 274±151 
nm, PDI- ≤0.3.   - -
[21]
SNEDDS Tamoxifen (TMX), 
naringenin (NG), Labrafil 
1944 CS, Caproyl-90, 
Labrasol, Transcutol P, Corn 
oil acconon C6, Soyabean oil, 
Sunflower oil, Sesame oil, 
PEG 400, Acrysol EC-35, 
Tween 80, Acconon CC-6, 
Transcutol HP.
Globule size 53 




By PBS (pH 7.4) MCF-7 
cells were washed and 100 
μL of TMX (5 mg/mL in 
PBS), incubated for 4 hrs. 
Formazon crystals were 
formed and it was thawed 
in DMSO (100 μL), 
absorbance was checked 
by microplate reader at 
570 nm.
In vivo antitumor 
activity:
Breast cancer was induced 
in female wister rats using 
7, 12-dimethyl benz-
anthracene (DMBA) with 
dose of 45 mg/kg for three 
weeks consecutively. 
Animals were separated 
and divided into different 
groups. After 10 weeks of 
DMBA dosing, drug was 
Cell line study showed that 
after 24 hrs of incubation, 
TMX-SNEDDS and TMX-NG–
SNEDDS showed 6.5 and 22-
fold increased cytotoxicity, 
respectively.
In vivo study  
The tumor size was estimated to 
be 15% for TMX-NG-
SNEDDS, which was smaller 
than from other formulations. 
The Kaplan-Meier scenario 
indicated species reproduction 
in the case of TMX-NG-
SNEDDS. The TMX-NG 
suspension and TMX-SNEDDS 
displayed 80% and 40% 
mortality, respectively.
[11]
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administered once in 3 
days to one group and 
positive control as saline 
given to another group 
orally. For 30 days tumor 
growth was observed and 
survival rate was 
monitored for 60 days. 







Transcutol HP, Capryol, 
Cremophore EL, Soluplus, 
Kollicoat MAE 30 DP 
(Methacrylic acid 
ethylacrylate copolymer), 
Hypromellose 2910, Kollidon 
90F, Acetonitrile, Finasteride 
and Methanol.
The particle sizes 
of F1-F3 and F4-
F13 formulation 
were found to be 
130 nm and 90-
110 nm, 
respectively. The 
PDI was less 
than 0.3 and the 
drug content was 
97.6-105.7%.  
Male Sprague-Dawley rats 
were taken and segregated 
in three different groups 
and fasted for 16 hrs. 1 mL 
(0.2%) of methylcellulose 
(MC) suspension, which 
contains DTS was given to 
the first group, 
conventional SEDDS is 
given to the second group 
and S-SEDDS is 
administered to the third 
group with dose of 2 
mg/kg.
SEDDS and SS-SEDDS 
showed significant increase in 
plasma level (within 3 hrs) as 
compared to drug suspension 
(12 hrs). AUC (0-24hrs) of S-
SEDDS was 3.9-fold more than 
the drug suspension and 1.3-
fold higher than SEDDS. The 
Cmax of SS-SEDDS was found 
to be 2.0 and 5.6 folds higher 
than SEDDS and drug 
suspension, respectively.  
[23]
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Table 2. SEDDS mediated drugs with improved oral solubility and bioavailability
Indication Bioactives/ Drugs References
Anti-coagulant Enoxaparin [57]
Antibiotic Daptomycin, Vancomycin, Ciprofloxacin [38-60]
Anti-hyperlipidemic Atorvastatin calcium [61]
Antioxidant Alpha-mangostin, Coenzyme Q10, Resveratrol [63-65]
Anticancer Enoxaparin, Diindolylmethane-14 (DIM-14),1, 1-bis (3′-indolyl)-1-(p-substituted 
phenyl) methanes (DIM-P), Erlotinib, Paclitaxel, E804, Lycopene
[66-73]




Benign prostatic hyperplasia Dutasteride [84]
Hypertension Nimodipine [85]
Cardiovascular activity Lovastatin [86]
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Table 3. Different anticancer drug containing SEDDS and its pharmacokinetic action
Drug/Active
constituent
Use Excipients Size (nm) Dose 
(mg/kg)









and human breast 
adenocarcinoma 
cell lines
 High stability in albumin and 
serum plasma
 Insignificant hemolytic 
activity
  Higher uptake on both cell 













64-292 20 and 
3.33
Labrador retriever
dogs and Sprague 
dawley rats
 Cmax and AUC0-t increased 
to 2.49 and 3 times, 
respectively in rats as 
compared to the native 
approach
 Cmax and AUC0-t increased 2 
and 2.92 times, 
respectively, in dogs as 








230–246 3.33 Labrador retriever
dogs
 Cmax and AUC0-t increased 
to 1.8 and 2.4 times, 







15, PEG 400, 
Capmul 
MCM
16.8–140 50 Beagle dogs  In contrast to the E804 
aqueous suspension, Cmax 
and AUC0-t improved to 6.3 










<100 10 Rabbits  Compared to PTX-
suspension, Cmax and AUC0-
t increased to 3.99 and 2.7 
times, respectively
[73]
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150-250 20 SD rats  In comparison to erlotinib, 
dextran-based S-SEDDS 
showed Cmax and AUC0-t 
increased to 2.4 and 2.1 
times, respectively
 In comparison to erlotinib, 
Aerosil-based S-SEDDS 
showed Cmax and AUC0-t 









37 50 Female landrace
pigs
 In comparison to Lycovit, 
Cmax and AUC0-t have 
increased to 2.85 and 2.3 
times, respectively
[75]
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Table 4. Description of SEDDS related patents especially for the period of 1999-2020 [91-130]









2020 Ethyl oleate, surfactant, co-surfactant, β-elemene [91]




2020 Astaxanthin,Quercetin,Cinnamon oil or Castor oil,Tween 





2020 Amino silicone oil,Epoxy resin,Reaction auxiliary 
agent,Solvent,End-capping agent
[93]
Chen Dexiang, Dong Lichun CN10952
8652A
2019 Oil phase (30-50%), Emulsi¦er (5-10%) and Pharmaceutical 
aqueous solution (40-60%)
[94]
Liu Yuling, Chen Xiaoguang, 
Zhang Jie et al.
CN11017
9750A
2019 Chlorogenic Acid, Oil phase, Emulsi¦er [95]
Anavi-Goffer S US201900
60300A1
2019 One CB2 receptor modulator,Self-emulsifying 
vehicle,Active agents (one antipsychotic agent,one GPR55 
modulator, one anti-inflammatory agent)
[96]




2019 Ticagrelor, Oil phase (Caprylic acid glycerides), Surfactant 
(Polyoxyethylenesorbitan fatty acid), Co-surfactant 
(Diethylene glycol monoethyl ether and Tetraglycol)
[97]
Chang-Shan, HsuWei-Hua 




2019 Hydrophilic drug,Solvents Surfactants,hydrophilic carriers. [98]
Mandip Sachdeva, Ketankumar 
Patel, Arun Rishi/Florida 




2019 Cell cycle and apoptosis regulatory protein-1,Lipidic 
excipient,Surfactant,Organic solvent (Dimethyl acetamide)
[99]
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2019 Diindolylmethane,Essential oil,Lauroyl polyoxyl-32 
glyceride,Propylene glycol caprylate, Polysorbate 80 or 
Tocopherol PEG 1000 succinate, Lecithin
[101]




2018 Diindolylmethane,Caprylocaproyl polyoxyl-8 glyceride, 
Lauroyl polyoxyl-32 glyceride,Phosphatidyl choline or 
lysophosphatidyl choline,Oleoyl polyoxyl-6 
glyceride,Poloxamer
[102]
Zhang Xiaofei Guo, Qiuting 
Shi Yajun, Zou Junbo et al.
CN10855
3417A
2018 Osthole,Oil phase,Surfactant and Co-surfactant [103]
XiongYongai, Zeng Yan CN10766
1287A
2018 Sanguisorbin, Oil phase (0.05‑0.25%), Surfactant 
(0.45‑0.65%), Co-surfactant (0.1‑0.3%) 
[104]




2018 Oil, A poorly water-soluble drug, and One or more 
surfactants
[105]









2018 Cannabinoid or a mixture of cannabinoids, 
Terpene,Emulsifier
[107]
S.O. Hustvedt, P.H. Olesen, G. 




2017 Eicosapentaenoic acid (EPA) 25%, Docosahexaenoic acid 
(DHA) 75%, Antioxidant, Super-disintegrant, Nonionic 
surfactant (Polysorbate 20, Polysorbate 40), Cationic 
surfactant (Quaternary ammonium compounds), 
Zwetterionic (dodecyl betaines) and solvent.
[108]




2017 Hydrophilic phase,Oily phase,Ionic polymer,Anionic 
surfactants,Cationic surfactants
[109]
D.S. Chow, Gupta P, Qi Y, et 




2016  Benzimidazole derivative (Methyl 5-benzoyl 
benzimidazole-2-carbamate), Oil (Propylene glycol 
dicaprylocaprate or caprylic triglyceride or capric 
triglyceride (19-56.5%), Dipolar aprotic solvent 
(dimethylsulfoxide, 5-10%) and Surfactant.
[110]
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2015 Poorly water-soluble drug,One surfactant,One polar lipid [111]
P. Nahat, P. Mandaogade, 




2015 Diacerein (10-90%), Labrafil (1-70%), polyoxyethylene 
glycerol esters of fatty acid (10-90%), Methylcellulose (2-




2015 Cyclodextrins,Oily or oleaginous substance,Antioxidant [113]





2015 Rosuvastatin,Surfactants, Co-surfactants [114]
Z. Liu, L. Yang, H. Yang, Y et 





2014 Butylphthalide, Ethoxypolyoxyethylene glyceride, 
Polyoxyethyleneoleate, Liquid lecithin, Polyoxyethylene 
castor oil, Coconut oil, Polyethyleneglycol glyceride, 
Almond oil oleate, Polyethyleneglycol glycerin ester, 








2014 Coenzyme Q10 (CoQ10) (70%), Volatile essential oil 
(peppermint oil, peppermint oil, menthol, anise oil and 
lemon oil), Surfactant and co-solvent, co-polymer of vinyl 
acetate and vinylpyrrolidone, Microcrystalline cellulose 
(MCC), Maltodextrin. 
[116]




2013 Polyoxyethylenesorbitan fatty acid ester emulsifier, Co-
emulsifier (glyceryl mono- or di-fatty acid esters) (2.5:1) 
(3.5:1), Oil (caprylic or capric triglyceride oil).
[117]




2012 Coenzyme Q10, Lipophilic co-surfactant, Hydrophilic 
surfactant, Lipophilic solvent (one or more than one).
[118]
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C. Kohli, S. Chopra, S. Arora, 
R, et al./ 
ArbroPharmaceuticals Ltd., 




2011 Curcuminoid (1-10%), Propyleneglycol monocaprylate 
(25-33%), Polyoxyethylene or Polyethoxyl derivative of a 
vegetable oil (35-45%), one or more co-surfactant (8-16%)
[119]




2010  No-NSAIDS, Short chain alcohol (ethanol, propylene 
glycol or glycerol, Phospholipid (egg lecithin), Semi-solid 
fat or oil.
[120]
Arvind Kumar Bansal, 




2010 Curcuminoids,Lipid carrier system,Fatty acid, Surfactants [121]
Sara Abelaira, Mariela Paula 




2008 Tipranavir,Vitamin E TPGS,One or more pharmaceutically 
acceptable solvents
[122]




hydroxypropylcarbamate, Salts, Esters, Polymorphic and 
pseudopolymorphic forms
[123]
Zhentao Liu, Liying Yang, 
Hanyu Yang/Shijiazhuang 





2007 Butylphthalide,Emulsifying agent,Excipient [124]
Gregory Lambert, Alain 
Razafindratsita, Jean-Sébastien 
garrigue et al./Novagali SA 
Yissum Research 
Development Company of 




2007 One or more taxoid(s), Vitamin E TPGS, One co-solvent 
selected from propyleneglycol and ethanol, One or more 
bile salts, Tyloxapol.
[125]




2005 Taxoid and at least one amphiphilic surfactant, Labrasol® [126]
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Simon Benita, Jean-Sébastian 
Garrigue, NeslihanGursoy et 
al./Novagali SA Yissum 
Research Development 




2003 One or more therapeutic agents,Vitamin E TPGS, Co-
solvent,Bile salts, Surfactant
[127]
J.T. Simonnet, O. Sonneville, 
S. Legret/L'Oreal (Paris, FR)
US627415
0B1
2001 Oily phase (vegetable oil, animal oil, mineral oil, silicon oil, 
synthetic oil), aqueous phase, anionic surfactant 
(Oxyethylenated derivatives and phosphoric acid fatty 
esters), one neutralization agent (organic bases and 
inorganic bases), one ionic amphiphilic lipid 
(alkylsulphonic derivatives and anionic amphiphilic lipids) 
(0.01-5%), transparency improving additives (glycols, 






2000 Cyclosporin, Non-ionic surfactant (HLB greater than 10), 
Aqueous mediun.
[129]




1999 Lipophillic drug (Cyclosporin), Surfactant (polysorbate 80), 
Glyceryl fatty acid ester, Polyethylene glycol, 
Polyglycolyzed glycerides (HLB 10 to 16).
[130]
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Figure 3. Some marketed products of SEDDS 
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